Trichinosis medical therapy

Trichinosis Microchapters
Home
Patient Information
Overview
Historical perspective
Classification
Pathophysiology
Causes
Differentiating Trichinosis from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Trichinosis medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Trichinosis medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Trichinosis medical therapy
CDC on Trichinosis medical therapy
Trichinosis medical therapy in the news
Blogs on Trichinosis medical therapy
Directions to Hospitals Treating Trichinosis
Risk calculators and risk factors for Trichinosis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Danitza Lukac

Overview

The mainstay of therapy for trichinosis are anthelmintics drugs such as albendazole or mebendazole.

Medical Therapy

Treatment for asymptomatic, abortive and mild patients:

• Administration of anthelmintics
• Administration of glucocorticoids if needed.

Treatment for pronounced and severe patients:

• Hospitalization
  • Compulsory for severe cases
• Administration of glucocorticoids, anthelmintics and analgesics.
• Administration of fluids and electrolytes

Antihelmintic Regimen

Trichinosis in adult and children ≥2yrs of age

• Preferred regimen (1): Albendazole 400 mg PO bid for 8 to 14 days OR Mebendazole 200-400 mg PO tid for 3 days, then 400-500 mg PO tid for 10 days
• Note:
  • Albendazole:
    • Pregnancy: Albendazole is pregnancy category C.
    • Lactation: It is not known whether albendazole is excreted in human milk.
    • Pedriatic patients: The safety of albendazole in children less than 6 years old is not certain. Studies of the use of albendazole in children as young as one year old suggest that its use is safe.
  • Mebendazole:
    • Pregnancy: Mebendazole is in pregnancy category C.
    • Lactation: It is not known whether mebendazole is excreted in breast milk. The WHO classifies mebendazole as compatible with breastfeeding and allows the use of mebendazole in lactating women.
    • Pedriatic patients: The safety of mebendazole in children has not been established.